Our Mission
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer.
News Releases
Year
News Releases
- Dec. 14, 2017 - Puma Biotechnology Added to NASDAQ Biotechnology Index Read
- Dec. 13, 2017 - Puma Biotechnology Announces Meeting of Scientific Advisory Group on Oncology in Europe to Review Neratinib for Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer Read
- Dec. 12, 2017 - Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer Read
- Dec. 11, 2017 - Puma Biotechnology Announces Positive Outcome of European Opposition Proceedings Patent Claims for Extended Adjuvant treatment Upheld Read
- Dec. 6, 2017 - Puma Biotechnology Presents Interim Results of Phase II CONTROL trial of Neratinib in Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer at the 2017 San Antonio Breast Cancer Symposium Read
- Nov. 22, 2017 - Puma Biotechnology and Specialised Therapeutics Asia Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Australia, New Zealand and South East Asia Read
- Nov. 13, 2017 - Puma Biotechnology’s 5-Year Analysis of Phase III ExteNET Study Published Online in The Lancet Oncology Data Demonstrates Continued Benefit from Neratinib after 5 years in Extended Adjuvant HER2-Positive Breast Cancer Read
- Nov. 9, 2017 - Puma Biotechnology Reports Third Quarter 2017 Financial Results Results include the initial sales of NERLYNX® in the U.S. Read
- Nov. 8, 2017 - Puma Biotechnology to Present at Stifel Healthcare Conference Read
- Nov. 2, 2017 - Puma Biotechnology Secures $100 Million Term Loan from Silicon Valley Bank and Oxford Finance Read
- Oct. 31, 2017 - Puma Biotechnology to Present at Credit Suisse Healthcare Conference Read
- Oct. 26, 2017 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results Read
- Sept. 18, 2017 - Puma Biotechnology to Present at Cantor Fitzgerald Healthcare Conference Read
- Sept. 8, 2017 - Puma Biotechnology Presents 5-Year Analysis of Phase III ExteNET trial in Extended Adjuvant HER2-Positive Breast Cancer at ESMO 2017 Congress Data Demonstrates Continued Benefit from Neratinib after 5 years Read
- Aug. 31, 2017 - Puma Biotechnology to Participate in Panel Discussion at Citi’s Biotech Conference Read
- Aug. 30, 2017 - Puma Biotechnology Announces Publication of Abstracts for ESMO 2017 Phase III ExteNET trial in Early Stage HER2-Positive Breast Cancer Read
- Aug. 25, 2017 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Aug. 9, 2017 - Puma Biotechnology Reports Second Quarter 2017 Financial Results Read
- Aug. 2, 2017 - Puma Biotechnology Receives Day-180 List of Outstanding Issues from Committee for Medicinal Products for Human Use (CHMP) Read
- July 31, 2017 - Puma Announces Availability of NERLYNX™ (neratinib) for Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer in the United States Read
- July 17, 2017 - U.S. Food and Drug Administration Approves Puma’s NERLYNX™ (neratinib) for Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer Read
- July 6, 2017 - Puma Biotechnology Completes Targeted Enrollment in Neratinib Phase III Metastatic Breast Cancer Trial Read
- June 3, 2017 - Puma Biotechnology Announces Positive PB272 Phase II Data from TBCRC 022 trial in Patients with HER2-Positive Metastatic Breast Cancer with Brain Metastases at the 2017 ASCO Annual Meeting Read
- May 31, 2017 - Puma Biotechnology to Present at the Jefferies 2017 Healthcare Conference Read
- May 24, 2017 - Puma Biotechnology Receives FDA Advisory Committee Support for Neratinib Read
- May 22, 2017 - Puma Biotechnology Announces Posting of FDA Oncologic Drugs Advisory Committee Briefing Documents for Neratinib Meeting Read
- May 17, 2017 - Puma Biotechnology Announces Publication of Neratinib Abstract for the 2017 ASCO Annual Meeting Read
- May 10, 2017 - Puma Biotechnology Reports First Quarter 2017 Financial Results Read
- May 9, 2017 - Puma Biotechnology to Present at Bank of America Merrill Lynch 2017 Health Care Conference Read
- April 17, 2017 - Puma Biotechnology Announces FDA Advisory Committee to Review Neratinib for the Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer Read
- April 4, 2017 - Puma Biotechnology Presents Interim Results of Phase II CONTROL trial of PB272 in Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer at the 2017 AACR Annual Meeting Read
- April 2, 2017 - Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2017 AACR Annual Meeting Read
- April 2, 2017 - Puma Biotechnology Presents Results from the Phase II SUMMIT trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer at the 2017 AACR Annual Meeting Read
- April 2, 2017 - Puma Biotechnology Launches Expanded Access Program for PB272 (Neratinib) for U.S. Patients with HER2-Positive Breast Cancer or HER2-Mutated Cancers Read
- March 2, 2017 - Puma Biotechnology to Present at Cowen’s Health Care Conference Read
- March 1, 2017 - Puma Biotechnology Reports Fourth Quarter and Full Year 2016 Financial Results Read
- March 1, 2017 - Puma Biotechnology Provides Update on Review of Marketing Authorisation Application for PB272 Read
- March 1, 2017 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2017 Read
- Feb. 14, 2017 - Puma Biotechnology to Present at RBC Capital Markets Healthcare Conference Read
- Feb. 8, 2017 - Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference Read
- Jan. 6, 2017 - Puma Biotechnology Expands Cohort in Phase II SUMMIT trial of PB272 in HER2 Mutation-Positive Cancer Patients Read
- Jan. 3, 2017 - Puma Biotechnology to Present at J.P. Morgan Healthcare Conference Read